Exclusive Patent License

An exclusive patent license and a patent assignment both restrict who can use a patent, but they differ fundamentally in who holds title: PATENT ASSIGNMENT: an assignment of a patent transfers ownership of the patent itself; after an assignment, the assignee is the new patent owner; the assignor no longer has rights in the patent (absent retained rights); assignments must be recorded at the USPTO to be effective against subsequent purchasers; EXCLUSIVE LICENSE: a license grants contractual rights to practice the patent; title remains with the licensor (patent owner); a fully exclusive license grants the licensee all patent rights — including the right to exclude the licensor itself — but this is still a license, not an assignment of ownership; WHY THE DISTINCTION MATTERS: (a) OWNERSHIP TITLE: the assignee owns the patent; the exclusive licensee does not; (b) STANDING TO SUE: a patent owner has clear standing to sue for infringement; an exclusive licensee's standing to sue depends on whether the license conveys 'all substantial rights' (Waterman v. Mackenzie, S.Ct. 1891 — exclusive licensee must join the patent owner if the license does not transfer all substantial rights); (c) TAX TREATMENT: patent assignments may receive capital gains treatment; royalties under a license are ordinary income; (d) TERMINATION: a license can be structured to terminate on breach, bankruptcy, or other conditions; an assignment is permanent unless the patent returns via a separate transaction; SPECTRUM OF EXCLUSIVITY: licenses range from fully exclusive (no other licensees, licensor also excluded) to exclusive in a field of use or territory (exclusive within a defined scope, nonexclusive outside) to nonexclusive (licensor may grant identical rights to anyone).

The right to sue an infringer without joining the patent owner is one of the most commercially significant questions in exclusive licensing: THE ALL-SUBSTANTIAL-RIGHTS TEST: an exclusive licensee has independent standing to sue for patent infringement if the patent owner has transferred 'all substantial rights' to the licensee; if all substantial rights are transferred, the licensee is effectively an assignee and can sue alone; WHAT 'ALL SUBSTANTIAL RIGHTS' MEANS: courts assess the totality of the rights conveyed, including: (a) the right to exclude others; (b) the right to sublicense; (c) no retained right by the licensor to practice the patent; (d) no field-of-use or geographic limitations that restrict the licensee's exclusivity; (e) the right to enforce the patent and collect damages; IF PATENT OWNER MUST BE JOINED: if the license does not transfer all substantial rights, the exclusive licensee must join the patent owner as a co-plaintiff for standing; Patent Owner's consent to be joined may be required; if the patent owner refuses to join, the licensee may be unable to bring suit; PRACTICAL APPROACH: well-drafted exclusive license agreements explicitly state: (a) whether the licensee has the right to sue independently or must obtain licensor consent; (b) whether the licensor will cooperate in enforcement (join suit at licensee's request and expense); (c) who controls litigation decisions and settlement; (d) how litigation proceeds and costs are shared; FIELD-OF-USE EXCLUSIVE LICENSES: a field-of-use exclusive license (e.g., exclusive for medical device applications) has exclusivity within the defined field but not outside it; the licensee can generally sue within the field; for infringement outside the field, the licensor must bring the action; OBLIGATION TO ENFORCE: some exclusive licenses include an obligation for the licensor to enforce the patent against infringers upon licensee request; failure to enforce may give the licensee rights to proceed alone.

Patent licenses are frequently limited to specific fields of use or geographic territories — allowing the licensor to grant exclusive rights to multiple licensees without conflict: FIELD-OF-USE RESTRICTIONS: a field-of-use restriction limits the license to a defined commercial application; examples: 'for use in human therapeutics only' (excluding veterinary use); 'for automotive applications only' (excluding aerospace); 'for commercial use in the United States only'; ANTITRUST SAFETY: field-of-use restrictions in patent licenses are generally procompetitive (they maximize the commercial exploitation of a single patent without creating horizontal restraints); General Talking Pictures Corp. v. Western Electric (S.Ct. 1938): patent owner can lawfully restrict a licensee to making the patented article for certain uses only; EXHAUSTION LIMITATION: patent exhaustion (first-sale doctrine) is not triggered when the licensee sells a product outside the authorized field-of-use; Mallinckrodt Inc. v. Medipart (Fed. Cir. 1992): a licensee who sells outside the authorized field infringes the patent; GEOGRAPHIC RESTRICTIONS: a license can be restricted to specific countries or regions; a US patent license can be limited to the eastern US; an international license can be limited to Europe; EXCLUSIVE TERRITORY: a licensee can be the exclusive licensee in a specific territory; the patent owner can grant different exclusive licenses to different companies for different territories; ANTI-ASSIGNMENT AND SUBLICENSING: exclusive licenses typically restrict assignment (the licensee cannot transfer its rights without licensor consent) and sublicensing (the licensee cannot grant sublicenses without consent); these restrictions prevent the licensee from converting an exclusive license into a general license without the licensor's agreement.

Exclusive patent licenses typically use more complex payment structures than nonexclusive licenses, reflecting the higher value conveyed: UPFRONT LICENSE FEE (LUMP SUM): an initial payment for the right to use the patent; in early-stage technology licenses, lump sums are often smaller than running royalties; for mature technology with proven demand, lump sums may be larger; RUNNING ROYALTIES: a percentage of net sales (revenues from licensed products, less defined deductions); typical royalty rates range from 1-3% for broad background technology to 5-15% for core technology with strong commercial position to 15-25%+ for breakthrough pharmaceutical or biotech inventions; MINIMUM ANNUAL ROYALTIES: a requirement that the licensee pay a minimum royalty each year regardless of actual sales; protects the licensor from a licensee who licenses exclusively then sits on the technology to block competitors; MILESTONE PAYMENTS: common in pharmaceutical and biotech: payments triggered by reaching defined development milestones (e.g., filing an IND, completing Phase 2 trials, receiving FDA approval); SUBLICENSE REVENUE SHARING: if sublicensing is permitted, a portion of sublicense fees received by the licensee is shared with the licensor (typically 10-50%); MOST FAVORED LICENSEE (MFL) CLAUSES: a provision that if the licensor later grants any other licensee terms more favorable than the exclusive licensee's terms, the exclusive licensee automatically receives the same better terms; BENCHMARK ROYALTIES: in FRAND licensing contexts, comparable license royalties are the most probative evidence of a reasonable rate (Ericsson v. D-Link); ROYALTY BASE: the portion of revenues on which the royalty is calculated; SSPPU (smallest salable patent-practicing unit) is preferred in royalty base disputes to avoid inflating the base with unrelated product value.

The treatment of patent licenses in bankruptcy and M&A is an area of significant complexity and commercial importance: SECTION 365 BANKRUPTCY AND PATENT LICENSES: when a patent licensor files for bankruptcy, it can 'reject' (terminate) executory contracts including patent licenses; Lubrizol Enterprises v. Richmond Metal Finishers (4th Cir. 1985): a licensee whose license is rejected loses the right to practice the patent; SECTION 365(n) PROTECTION (AIA amendment to Bankruptcy Code): Congress added § 365(n) to protect IP licensees: if a licensor rejects a patent license in bankruptcy, the licensee has two options: (a) treat the license as terminated and file a claim for damages; (b) RETAIN RIGHTS under the license for the duration of the license and any renewal, paying royalties and waiving any right to setoff; § 365(n) SCOPE: protects trademark licensees who use the mark in connection with licensed technology? No — Supreme Court in Mission Product Holdings v. Tempnology (S.Ct. 2019): rejection of a trademark license (not a patent license) under § 365 does NOT strip the licensee of its right to continue using the trademark; reasoning broadly applies the 'breach not rescission' principle to trademark licenses; M&A TREATMENT: when the patent owner is acquired, the acquirer takes the patent subject to existing exclusive licenses; the exclusive licensee's rights survive the acquisition (a license runs with the patent); ASSIGNMENT OF LICENSES: most exclusive licenses prohibit assignment without licensor consent; in an M&A context, an acquirer of the licensee may need consent from the licensor to have the license continue; CHANGE-OF-CONTROL CLAUSES: some patent licenses terminate if the licensee undergoes a change of control (especially to a competitor of the licensor); due diligence in M&A should review all patent licenses for change-of-control provisions.